IOT
IOT
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
0
$0
Total Volume
$0
66 transactions
Net Activity
+$0
Net buying
Sentiment Rating
Neutral / BalancedCEO Conviction Index
No Recent Signal
Key Drivers
- •Balanced trading volume with net neutral buying and selling activity.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
IOT has an insider buy conviction of 50%, compared to the Unknown sector buy average of 50%. IOT ranks #121 in insider activity out of 287 tracked companies in its industry.
Multiple Insiders
S - Sale Insiders
$0 total
Over the last 90 days, corporate insiders at IOT (IOT) engaged in a total of 66 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 0 were sales. The total volume of insider trading reached $0.
The net insider activity for IOT shows a net buying bias of $0. This activity represents a 50% buy ratio, suggesting that insiders are currently neutral on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (S - Sale Insiders), who traded 151.1K shares valued at $0 on Sep 18, 2026.
Quick Actions
Related News & Analyst Reports
Read original insights and educational research covering IOT and the Unknown sector.
The Biotech Executive Playbook: Tracking Clinical Phase SEC Filings
An empirical study on how clinical-stage biotech executives execute Form 4 open-market purchases ahead of trial data releases, outlining the regulatory gaps and alpha potential of clinical insider tracking.
Tracking Insider Activity in Biotech: High Stakes and Hidden Signals
Biotech insiders possess unique asymmetric information, clinical results, FDA feedback, partnership negotiations. This guide explains how to track Form 4 activity at pre-commercial biotechs, what position sizes matter, and how to avoid false signals near data events.
Venture-Backed Biotech IPOs: Inside the 2026 Buying Spree
2026 saw a resurgence of venture-backed biotech IPOs, accompanied by unusually high post-lockup insider buying. This report documents the specific Form 4 cluster events, purchase sizes, and 90-day price performance across a dozen recent biotech offerings.
Biotech Insider Buying: Analyzing Clinical Trial Catalysts
Biotech insiders walk a legal tightrope near trial readouts. This report identifies statistically significant buying clusters at small-cap biotechs 30-90 days before Phase 2 and Phase 3 data announcements.
Why Biotech Insiders Purchase Prior to Phase 3 Results
Buying stock before Phase 3 results is the highest-risk insider trade in biotech. This report examines the legal boundaries, the statistical frequency of such purchases, and whether insiders who buy pre-Phase-3 have historically outperformed those who buy after.
Analyzing the Correlation Between R&D Spending and Insider Confidence
Do executives buy more stock when R&D budgets surge? This study correlates quarterly R&D expenditure disclosures with insider purchase timing across 200 tech and biotech companies from 2020-2025.
FAQs About IOT Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for IOT.